Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world adjuvant apatinib study in high-risk recurrent hepatocellular carcinoma after surgery
ChiCTR2000029799Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Chinese PLA General Hospital. Primary endpoint: Effectiveness. Started Sep 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000029799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029799.